In Sluggish World Economy, Array Companies Encouraged by China's Fast Growing Clinical Market | GenomeWeb

"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.

"The market is growing and the potential is enormous," Sheng told BioArray News in an interview during a recent workshop in Hangzhou, a city just west of Shanghai. "Everybody agrees that the China market is exploding, not only on the research side but on the clinical side."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.